相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Disruption of Growth Hormone Receptor Signaling Abrogates Hepatocellular Carcinoma Development
Abedul Haque et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA (2022)
HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk
Jeffrey S. Morris et al.
HEPATOLOGY (2021)
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister et al.
NATURE (2021)
Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH
Michael Dudek et al.
NATURE (2021)
T cells in NASH and liver cancer: pathology and immunotherapy
Jordan Hindson
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister et al.
NATURE (2021)
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Genome-Wide Profiling of Laron Syndrome Patients Identifies Novel Cancer Protection Pathways
Haim Werner et al.
CELLS (2019)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Autocrine Human Growth Hormone Promotes Invasive and Cancer Stem Cell-Like Behavior of Hepatocellular Carcinoma Cells by STAT3 Dependent Inhibition of CLAUDIN-1 Expression
Yi-Jun Chen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Growth hormone receptor antagonism suppresses tumour regrowth after radiotherapy in an endometrial cancer xenograft model
Angharad Evans et al.
CANCER LETTERS (2016)
Human growth hormone and human prolactin function as autocrine/paracrine promoters of progression of hepatocellular carcinoma
Xiangjun Kong et al.
ONCOTARGET (2016)
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2015)
Development and Validation of Insulin-like Growth Factor-1 Score to Assess Hepatic Reserve in Hepatocellular Carcinoma
Ahmed O. Kaseb et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Mechanism of Activation of Protein Kinase JAK2 by the Growth Hormone Receptor
Andrew J. Brooks et al.
SCIENCE (2014)
Clinical and Prognostic Implications of Plasma Insulin-Like Growth Factor-1 and Vascular Endothelial Growth Factor in Patients With Hepatocellular Carcinoma
Ahmed O. Kaseb et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
In Vivo Targeting of the Growth Hormone Receptor (GHR) Box1 Sequence Demonstrates that the GHR Does Not Signal Exclusively through JAK2
Johanna L. Barclay et al.
MOLECULAR ENDOCRINOLOGY (2010)
The growth hormone receptor: mechanism of activation and clinical implications
Andrew J. Brooks et al.
NATURE REVIEWS ENDOCRINOLOGY (2010)
Influence of recombinant human growth hormone (rhGH) on proliferation of hepatocellular carcinoma cells with positive and negative growth hormone receptors in vitro
Suyi Li et al.
TUMORI JOURNAL (2010)
Transgenic mice overexpressing GH exhibit hepatic upregulation of GH-signaling mediators involved in cell proliferation
Johanna G. Miquet et al.
JOURNAL OF ENDOCRINOLOGY (2008)
JAK2, but not Src family kinases, is required for STAT, ERK, and Akt signaling in response to growth hormone in preadipocytes and hepatoma cells
Hui Jin et al.
MOLECULAR ENDOCRINOLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Nuclear targeting of the growth hormone receptor results in dysregulation of cell proliferation and tumorigenesis
Becky L. Conway-Campbell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis
Hashem B. El-Serag et al.
GASTROENTEROLOGY (2007)
Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: Implications for cancer therapy
Donghua Yin et al.
CLINICAL CANCER RESEARCH (2007)
The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth
Jana Divisova et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Tissue-specific regulation of growth hormone (GH) receptor and insulin-like growth factor-I gene expression in the pituitary and liver of GH-Deficient (lit/lit) mice and transgenic mice that overexpress bovine GH (bGH) or a bGH antagonist
K Iida et al.
ENDOCRINOLOGY (2004)
Pegvisomant: structure and function
S Pradhananga et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2002)
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
AJ van der Lely et al.
LANCET (2001)
Overexpressed growth hormone (GH) synergistically promotes carcinogen initiated liver tumour growth by promoting cellular proliferation in emerging hepatocellular neoplasms in female and male GH transgenic mice
KJ Snibson et al.
LIVER (2001)
Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice
IE McCutcheon et al.
JOURNAL OF NEUROSURGERY (2001)
Increased expression of growth hormone and prolactin receptors in hepatocellular carcinomas
T García-Caballero et al.
ENDOCRINE (2000)
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
PJ Trainer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
